Request Demo
Last update 26 Nov 2025
Cilofexor/Firsocostat
Last update 26 Nov 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms FXR agonist/ACC inhibitor (Gilead) |
Target |
Action inhibitors, agonists |
Mechanism ACC1 inhibitors(Acetyl-CoA carboxylase 1 inhibitors), ACC2 inhibitors(Acetyl-CoA carboxylase 2 inhibitors), FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC32H33Cl3N4O8 |
InChIKeyCUWTTWVBVUZPAP-UHFFFAOYSA-N |
CAS Registry2253764-93-9 |
View All Structures (3)
Related
1
Clinical Trials associated with Cilofexor/FirsocostatNCT04971785
A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
100 Clinical Results associated with Cilofexor/Firsocostat
Login to view more data
100 Translational Medicine associated with Cilofexor/Firsocostat
Login to view more data
100 Patents (Medical) associated with Cilofexor/Firsocostat
Login to view more data
100 Deals associated with Cilofexor/Firsocostat
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Compensated cirrhosis | Phase 2 | United States | 09 Aug 2021 | |
| Compensated cirrhosis | Phase 2 | Japan | 09 Aug 2021 | |
| Compensated cirrhosis | Phase 2 | Australia | 09 Aug 2021 | |
| Compensated cirrhosis | Phase 2 | Canada | 09 Aug 2021 | |
| Compensated cirrhosis | Phase 2 | France | 09 Aug 2021 | |
| Compensated cirrhosis | Phase 2 | Spain | 09 Aug 2021 | |
| Fibrosis | Phase 2 | United States | 09 Aug 2021 | |
| Fibrosis | Phase 2 | Japan | 09 Aug 2021 | |
| Fibrosis | Phase 2 | Australia | 09 Aug 2021 | |
| Fibrosis | Phase 2 | Canada | 09 Aug 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 457 | (SEMA + CILO/FIR FDC) | rivzkkpcqk = hvqdxlsxpn bymeuiylqq (udismkcfui, ygrdmhsgsk - orhrvbbfgz) View more | - | 26 Nov 2025 | ||
PTM SEMA+PTM CILO/FIR (PTM SEMA + PTM CILO/FIR) | rivzkkpcqk = dzvmyprfbh bymeuiylqq (udismkcfui, kmwengyslq - oqgbxcyfoo) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free